NasdaqGS:MYGNBiotechs
Why Myriad Genetics (MYGN) Is Down 49.0% After Cutting 2026 Revenue Outlook On Prenatal Weakness
In late July 2026, Myriad Genetics reported second-quarter results showing revenue of US$190.7 million versus US$213.1 million a year earlier, alongside a reduced full-year 2026 revenue outlook of US$770 million to US$790 million due to weaker Prenatal Health test volumes and more cautious assumptions for revenue per test.
Despite the revenue decline, the company’s net loss narrowed sharply to US$43.2 million from a very large loss a year ago, highlighting significant cost or non-operational...